Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Besremi in pre-fibrotic and low/intermediate-1 risk myelofibrosis
NCT05731245Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in primary myelofibrosis (PMF), sponsored by National Taiwan University Hospital. Started Feb 2023; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
primary myelofibrosis (PMF)
Beyond the preview
Go deeper on NCT05731245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731245.